Pfizer Inc. $PFE Shares Purchased by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 118.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 342,842 shares of the biopharmaceutical company’s stock after acquiring an additional 185,704 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in Pfizer were worth $8,177,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in Pfizer during the second quarter worth about $29,000. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer in the third quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the 2nd quarter valued at approximately $30,000. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 2.8%

NYSE:PFE opened at $27.24 on Friday. The company has a market capitalization of $154.88 billion, a PE ratio of 20.03 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The stock has a fifty day simple moving average of $25.61 and a 200-day simple moving average of $25.10. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio is presently 126.47%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PFE shares. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Morgan Stanley decreased their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.06.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.